Since prescribing and deprescribing clinical tools do not consider preferences, life expectancy, and goals of care, it is essential to understand what matters to the patient and/or caregiver
April 2, 2025: Wegovy Maker Novo Nordisk Reports Record Earnings Due to Wegovy Sales The controlling shareholder of Wegovys manufacturer Novo Nordisk doubled their income in 2024, according to their 2024 earnings report
Understanding GLP-1 Medical Weight Loss Before comparing options, Nocatee residents should understand what makes GLP-1 programs effective
A dedicated trial in adults with obesity found no evidence of delayed gastric emptying at week 20 for semaglutide 2.4 mg, while still showing reduced appetite, reduced cravings, and lower energy intake
And it doesn't trigger the hormonal response that drives muscle protein synthesis
Benefits and Risks Key takeaways: Microdosing is the off-label use of GLP-1 receptor agonists at doses lower than those approved for the treatment of diabetes or obesity
